Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 10 best defensive stocks to buy in a volatile market. On July 4, the company entered into a multi-year agreement with Modella AI.

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

One of the first and most promising uses scientists envision for the rapidly evolving technology of quantum computing is a new approach to drug development. A quantum computer could, in theory ...

While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to signals of drug activity, William Blair said, though the analysts pointed to ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed 53% in the aftermath of the readout. Altimmune’s dual GLP-1/glucagon agonist ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect.

With extensive experience across the full lifecycle of ADC development—from target validation and potency analysis in early R&D to preclinical/clinical quality evaluations—he has successfully ...

Many sponsors defer the pediatric strategy as they are often perplexed by the challenges presented by pediatric oncology drug development (model of action relevancy to pediatric population, budget, ...